Ironwood Pharmaceuticals reported second quarter 2026 total revenue of $113.0 million and GAAP diluted EPS of $0.31. While revenue missed consensus estimates of $118.0 million, EPS beat expectations of $0.26, leading the company to raise its full-year financial guidance.

Key Highlights

  • Raised full-year 2026 total revenue guidance to a range of $460 million to $485 million and adjusted EBITDA guidance to over $310 million.
  • LINZESS U.S. net sales grew 14% year-over-year to $282.3 million, driven by a 4% increase in prescription demand and improved net pricing.
  • The company confirmed its confirmatory Phase 3 STARS-2 trial for apraglutide is now actively recruiting patients and it repaid $200 million of convertible notes during the quarter.